Clinical cancer research : an official journal of the American Association for Cancer Research 10/2014; DOI: 10.1158/1078-0432.CCR-14-0489
Source: PubMed Phase I, Dose-Escalation Study of the Targeted Cytotoxic LHRH Analog AEZS-108 in Patients with Castration- and Taxane-Resistant Prostate Cancer.
ABSTRACT Background: AEZS-108, formerly AN-152, is a cytotoxic hybrid molecule consisting of an LHRH agonist moiety covalently coupled to doxorubicin, allowing it to deliver doxorubicin selectively to cells expressing LHRH receptors. LHRH receptors are expressed on the cell membrane of many tumors, including prostate cancer (PC). This Phase I study determined the maximum tolerated dose (MTD) of AEZS-108 in men with taxane- and castration-resistant PC (CRPC) while providing additional information on the safety profile and efficacy of this agent. Materials and Methods: AEZS-108 was administered as an intravenous infusion every 21 days until progression or unacceptable toxicity in cohorts of 3 or 6 patients until the MTD was reached. Blood was collected for capture of circulating tumor cells (CTCs) to visualize internalization of AEZS-108, an auto-fluorescent molecule. Results: The MTD of AEZS-108 in this cohort was 210 mg/m2, which was lower than that seen in a Phase I study conducted in women with endometrial or ovarian cancers. The dose limiting toxicity was persistent neutropenia. Three patients had a PSA response with an additional 10 patients maintaining PSA stable disease. Of the 10 patients evaluable by RECIST criteria, 9 achieved stable disease. AEZS-108 internalization in CTCs was routinely visualized using its auto-fluorescence. Conclusion: These findings show that AEZS-108 has an acceptable safety profile and a signal of efficacy, lowering PSA in heavily pretreated patients with PC, and that internalization of AEZS-108 in PC CTCs may be a viable pharmacodynamic marker. A phase II study in men with PC is ongoing.
Since it tests for HGH (human growth hormone) orally and is not a blood test the NFL would be interested Macrilen for the purpose of finding concussions. Publicity like this would be enormous. Just think of all the college sports where concussions are rampant, football, soccer, rugby just to name a few. There could be hundreds of thousands of tests through out the world since AEZS has worldwide rights until 2027.
Sources: NFL, Union Showing Renewed Interest In Negotiating HGH Testing Policy
Published September 4, 2014
The NFL and NFLPA are "showing renewed interest in attempting to implement changes to the sport’s drug policies that would include players being blood-tested" for HGH, according to sources cited by Mark Maske of the WASHINGTON POST. Sources on both sides said that there was an "increased willingness to try to find a way to overcome the remaining obstacles in the discussions and finish the long-awaited agreement."
Blah blah blah. Live in the past dsco. How many id's do you have? Can't believe you just put all your energy into this one stock. You should put all your posts into a book it would be longer than War and Peace. Let's see where this stock is in the beginning of November. I say up .
Actually raising cash after the Peri failure was a good move looking back. That was equal to raising cash at over 5 bucks a share now. With bio's how else are they going to raise money? You complain about bad management before so now they got more qualified people in the top positions and the company is moving forward you still complain.. The new management filed the NDA where old management was dragging it's feet. Egromed a professional company running the Aezs-108 phase 3 trial plus they are putting in 10 million for a single digit royalty. The recruitment has been good. Results 1st half of 2015. The Ascend deal should bring in a small amount of income look up the deal for details.. If Aezs-108 is positive that will be huge since it is a delivery system and can be used for other cancers the pps will soar. You still talk about Engle who has been gone for years, why is that? Some of us long time longs do see a big improvement with the way the company is run and I am glad to see someone making aggressive changes. The pps will rise as the FDA decision is in a few weeks. Since Macimorelin is a test with over 90% success rate and will be the only oral test for HGH there is a high chance of approval. If Aezs-108 is successful maybe Aezs could be the next Jazz.. The pps will rise with all the events coming up. This is the best position Aezs is at in a long time. Also the total amount Aezs can raise for selling stock is 15 million. There is also only 6.5 % of the float short which is small. Also look up the salaries for management. They are actually low compared to other bio's with less to offer than Aezs. Inquiring minds want to know your agenda dsco since you state you have no fi
nancial l interest in Aezs.
What does Nps have to do with Aezs? They have drug ,Aezs has a test. Nothing to do with each other. dsco is right this MB is deranged.
On this deranged message board as you call it you are the #1 poster in total words by far. Usually when someone has an agenda there is a reason for it, yet you refuse to say what your agenda is since you have no stock. That makes you an odd ball.Thousand word rants to say the same thing over and over. For a penny stock the time you put in you lengthy posts is bizarre.I don't see you on any other boards than this one so you must have a lot of aliases. You are loony tunes with your obsession with this stock. Out of curiosity what else are you obsessed with besides Aezs? Let's take a poll and see how many paragraphs Dsco,s response will be. I say 5.
You are just a paid basher. You never stated what your interest is in this stock since you said you are neither long or short. Please tell us the reason since this is not normal behavior. Good God! Look at the length of this post. Does this set a record as the longest in MB history? You must of been fired from Aezs or maybe you were a stalker there. I agree the past of Aezs was poor but they changed the management and have a pipeline with solid potential drugs on the horizon. Even Apple was on the verge on disappearing years ago. Not that Aezs is an apple but just an example of a down and out company reversing course. You can live in the past spewing the same stuff over and over. I will look more at the future potential of this stock and the nice turnaround it is having now. It's a beautiful day today , you should go outside and stop to smell the roses.
The company needed the ATM to advance the programs which include a possible FDA drug approval Nov. 5th and a phase 3 trial with results in the first half of 2014.If that trial is successful than AEZS-108 can be used for other cancers since it is a delivery system. Then the pps will be a lot higher. Since they have no revenue, where else is the money going to come from. Dsco you fail to believe the company is in a turnaround. That's your prerogative. Matter of fact the company is up 40% since you predicted a r/s and pps under a dollar. I guess you were wrong there.Seems lately your more wrong than right and the rest of you opinions are pure speculation. It is real easy for you to be an arm chair quarterback.
Gilead phase 2 trial just failed for pancreatic cancer. Maybe they will be interested in AEZS-108. This is an article from last year.
Oncotarget. May 2013; 4(5): 751–760.
Published online Jun 3, 2013.
Powerful Inhibition of Experimental Human Pancreatic Cancers by Receptor Targeted Cytotoxic LH-RH analog AEZS-108
It is a long article and states, Cytotoxic LH-RH analog, AEZS-108, may be a useful agent for the treatment of LH-RH receptor positive advanced pancreatic carcinoma.
It is accumulation as of 12:50 Stock Money Flow WSJ
Uptick/Downtick Trade Ratio
Net Money Flow ($)
Money flow gives a snapshot of relative buying and selling pressure in a stock. A ratio above one suggests greater buying pressure, below one suggests greater selling.
Uptick/Downtick Trade Ratio
Net Money Flow ($)
Money flow gives a snapshot of relative buying and selling pressure in a stock. A ratio above one suggests greater buying pressure, below one suggests greater selling
Both great numbers.
Rebuttal dsco : 1) They were fired for taking to long to file aezs-108. Dodd knew he needed a better team for aezs-108 which is more important.
2)A development company has low to no revenue . All companies use safe harbor, nothing unusual .
3) Can't rule out partnership for drugs in pipeline.Mac approval high based on test results.
4) Kerx did the peri trial for AEZS. Look up phase 2 for end cancer. It did extend survival substantially.
5) Look up agreement. You are totally misleading here.
6)Ergomed has experience running trials. How do you there is no contribution yet? The money would be applied to the trial not a cash payment.
7) This is a turn around company. Many new personal in top positions. The old guard responsible for the past are mostly gone.
8) AEZS has no revenue like many other development bio's.
9) For a filed NDA and a phase 3 trial and 33 million cash, valuation is extremely low compared to many bio's that are just in a phase 2.
10) When a company reorganizes the stock always takes a hit. The future never looked better now for AEZS. see #9#7.
They never refiled idiot. Liers coming out of the woodwork.
Besides Macrilen's PDUFA date on 11/5/14 which will propel the stock up a few bucks we have the phase 3 trial of ZOPT_EC (AEZS-108). Since it is an open label trial and hundreds are enrolled already, some over a year, there is a good chance that many people know that it is working. If it does work it can be used to target many other cancers. With the worldwide rights to both drugs AEZS-108 could make this stock soar into the double digits. That will be pertinent to a partnership. What a bargain at $1.40.
Spryoke I think you might be wrong . Google ASCO2014 abstract#tps5630. It gives a nice summary. I got 13.7 from phase 2 results.
is the primary endpoint for the phase 3 AEZS-108 trial. The overall survival rate has to be 12 months vs 9 months to be significant.. In the phase 2 trial that was completed the overall survival was 13.7 months. So it seems that AEZS-108 has a great chance to be successful. With the FDA decision on AEZS-130 due the beginning of Nov. investors are starting to see the bargain basement price AEZS is.
Dilution for a biotech like AEZS is normal when there is no income. If AEZS-130 is approved in Nov. and there are positive results for AEZS-108 this stock will soar. If poor results this stock is done. So far everything looks positive. Past history has no relevance because there has been a complete replacement of management except for Turpin. Remember KERX was 25cents years ago and CITI Group was $500 at it's high now it's 50 bucks. So what is the relevance that years ago AEZS was $70 after the reverse split. A biotech like AEZS is event driven and if any of these events in the future are positive we can say goodby to $1.28 and dsco who lives in the past and keeps rehashing the same old dribble for his own agenda. Remember dsco states he owns no AEZS stock. Just a fact for the new people.